12/20
08:19 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
Low
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
12/19
07:13 am
orka
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody [Yahoo! Finance]
Low
Report
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody [Yahoo! Finance]
12/19
07:00 am
orka
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Low
Report
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
12/18
07:09 am
orka
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]
Medium
Report
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]
12/18
07:00 am
orka
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
Medium
Report
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
12/11
08:32 am
orka
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% [Yahoo! Finance]
Low
Report
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% [Yahoo! Finance]
11/25
08:05 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
High
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
11/19
11:41 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock.
Medium
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock.
11/19
08:00 am
orka
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
Medium
Report
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
11/13
06:05 pm
orka
Oruka Therapeutics GAAP EPS of -$1.46 misses by $1.08 [Seeking Alpha]
High
Report
Oruka Therapeutics GAAP EPS of -$1.46 misses by $1.08 [Seeking Alpha]
11/13
04:29 pm
orka
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/13
04:25 pm
orka
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/4
07:00 am
orka
Oruka Therapeutics to Present at Multiple November Investor Conferences
Low
Report
Oruka Therapeutics to Present at Multiple November Investor Conferences
10/31
08:35 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
High
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
10/11
08:07 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $49.00 price target on the stock.
Low
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $49.00 price target on the stock.
10/7
08:17 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $45.00 price target on the stock.
Low
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $45.00 price target on the stock.